Spravato® (esketamine) is an FDA-approved nasal spray specifically indicated for adults with treatment-resistant depression (TRD), which is a condition in which at least two oral antidepressants have failed to provide adequate relief. Unlike traditional antidepressants that can take weeks to build up in the system, Spravato® works by targeting NMDA (N-methyl-D-aspartate) glutamate receptors in the brain, rapidly restoring synaptic connections that depression is thought to disrupt. Many patients and clinicians report Spravato® rapid depression relief within hours to days of the first treatment session, making Spravato® a breakthrough option for those who have long struggled to find relief.
Spravato® is administered under medical supervision at a Spravato® treatment center for mental health, where patients self-administer the nasal spray and are monitored for at least two hours post-dose. This protocol ensures both safety and efficacy, as the medication can cause temporary side effects, such as dissociation or dizziness, immediately after administration.
Treatment typically involves twice-weekly sessions during an induction phase, followed by a maintenance schedule tailored to the patient’s response. For individuals living with treatment-resistant depression, Spravato® offers a clinically validated, fast-acting path toward symptom relief and improved quality of life, often when all other options have been exhausted.
How Spravato® Works Differently From Traditional Antidepressants
Most traditional antidepressants, including SSRIs and SNRIs, work by targeting the brain’s monoamine neurotransmitters, such as serotonin, norepinephrine, and dopamine. While effective for many people, these medications require consistent daily use over four to six weeks before meaningful symptom relief is felt, and a significant portion of patients never achieve full remission.
Spravato® treatment for mental health takes an entirely different approach. Rather than targeting the monoamine system, Spravato® acts on NMDA glutamate receptors, which are key players in synaptic plasticity and mood regulation. By blocking these receptors, Spravato® triggers a rapid increase in glutamate activity, which promotes the regrowth of synaptic connections in brain regions affected by chronic depression. This neuroplasticity-driven mechanism is what sets Spravato® apart from every oral antidepressant currently on the market.
The speed and distinctiveness of Spravato®’s mechanism make it especially valuable for patients with treatment-resistant depression who cannot afford to wait weeks for relief or who have already exhausted conventional medication options. Because Spravato® works on a fundamentally different pathway, it can be effective even when multiple antidepressants have failed.
Spravato® is always used alongside a newly initiated or current oral antidepressant, creating a complementary treatment strategy that addresses depression from multiple biological angles simultaneously. For patients and providers seeking Spravato® rapid depression relief, Spravato® represents a significant evolution in how treatment-resistant depression is understood and managed.
How Quickly Does Spravato® Provide Relief?
One of the most clinically significant advantages of Spravato® is the speed at which it can begin alleviating depressive symptoms. Many patients with treatment-resistant depression (TRD) experienced meaningful symptom reduction within 24 hours of their very first dose. This Spravato® rapid depression relief is directly tied to its unique mechanism of action. B
By modulating NMDA glutamate receptors and stimulating synaptic neuroplasticity, the brain begins rebuilding disrupted neural connections almost immediately after administration. For individuals who have spent months or years cycling through ineffective medications, this fast-acting response can be life-changing. In cases involving active suicidal ideation with intent, the speed of relief carries critical clinical urgency.
While many patients feel improvement quickly, Spravato® is not a one-time treatment. The full therapeutic benefit is achieved through a structured dosing schedule: twice-weekly sessions during the four-week induction phase, followed by weekly, then biweekly, maintenance sessions based on individual response. Some patients experience robust relief early in treatment, while others see gradual improvement that deepens over successive sessions.
Mental Health Treatment That Works
Call 949-625-0564What our customers are saying
What to Expect During a Spravato® Treatment Session
Before beginning Spravato® therapy for treatment-resistant depression, understanding what happens during each session can help ease uncertainty and set the stage for a safe, effective experience.
- Before Your Session: Before each appointment, patients should avoid eating for at least two hours and refrain from drinking liquids (other than water) for at least 30 minutes before administration. It is also essential to arrange for a driver, as patients are not permitted to drive or operate heavy machinery on the day of their treatment due to the medication’s temporary sedative and dissociative effects.
- Self-Administering the Nasal Spray: Spravato® is self-administered under the direct supervision of a licensed healthcare provider in a certified treatment center. Patients use the nasal spray device to deliver the prescribed dose. The device is designed for ease of use, and clinical staff are present throughout to guide the process and ensure proper technique.
- The Observation Period: Following administration, patients are monitored on-site for a mandatory minimum of two hours. During this window, clinical staff track vital signs and assess for potential side effects, including dizziness, nausea, dissociation, or elevated blood pressure. Most side effects are temporary and resolve before the observation period ends.
- What You May Feel During the Session: It is common to experience perceptual changes, a sense of detachment, or mild sedation during and shortly after administration. Patients are encouraged to rest comfortably during this time, and many report that these sensations subside well before they are cleared to go home.
- Going Home: Once the observation period is complete and clinical staff confirm that the patient is stable, the patient is discharged to the care of a responsible adult who can drive them home. Patients should plan to rest for the remainder of the day and avoid making important decisions or signing legal documents until the following morning.
How Often Is Spravato® Administered?
Spravato® follows a structured, phase-based dosing schedule designed to deliver rapid relief in the initial weeks of treatment, then transition to a long-term maintenance regimen tailored to each patient’s clinical response.
- Induction Phase (Weeks 1–4): During the first four weeks of treatment, Spravato® is administered twice per week. This intensive schedule is intended to rapidly reduce depressive symptoms, establish a therapeutic response, and begin the neuroplasticity-driven healing process that makes esketamine uniquely effective against treatment-resistant depression.
- Maintenance Phase I (Weeks 5–8): After completing the induction phase, dosing frequency is reduced to once per week for the following four weeks. This phase reinforces and consolidates the symptom improvements achieved during induction while the body and brain continue to adapt to treatment.
- Maintenance Phase II (Week 9 and Beyond): Beginning in week nine, patients transition to a biweekly dosing schedule. This long-term maintenance phase is designed to sustain remission, prevent relapse, and support ongoing mental wellness in patients with treatment-resistant depression.
- Individualized Adjustments: While the standard dosing schedule serves as the clinical framework, a patient’s treatment provider may adjust the frequency or duration of any phase based on individual symptom response, tolerability, and overall progress. Some patients may continue weekly sessions into the long-term maintenance phase if their provider determines it is clinically appropriate.
- Ongoing Oral Antidepressant Use: Throughout all phases of Spravato® treatment, patients are required to continue taking an oral antidepressant as directed. This combination approach addresses depression through two complementary neurological pathways, maximizing the likelihood of achieving and sustaining full remission from treatment-resistant depression.
Key Takeaways on Spravato® Rapid Depression Relief
- Spravato® Is FDA-approved for adults who have tried and failed at least two oral antidepressants.
- Unlike SSRIs and SNRIs, which target serotonin and dopamine, Spravato® modulates NMDA glutamate receptors, triggering rapid synaptic neuroplasticity.
- One of Spravato®’s most clinically significant advantages is its speed.
- Every Spravato® session takes place in a certified clinical setting under medical supervision.
- Spravato® is always administered alongside a current or newly initiated oral antidepressant.
If you’re struggling with depression and seeking Spravato® rapid depression relief, reach out to Moment of Clarity’s mental health centers in Southern California. We offer Spravato®, a treatment designed to provide rapid relief for depression. To find out if you qualify for this innovative therapy, please call Moment of Clarity at 949-625-0564. Our dedicated team is ready to assist you on your journey to better mental health.
Resources
- Spravato.com – How Can SPRAVATO® Help?
- Keck School of Medicine of USC – Spravato (Esketamine Nasal Spray)
- Johns Hopkins Medicine – Esketamine for Treatment-Resistant Depression
